Methods of treating joint disease, disorders, and conditions with tissue inhibitors of matrix metalloproteinase

A method of lubricating an osteoarthritic joint in a subject in need thereof, wherein the osteoarthritis of the joint is associated with degradation of articular cartilage by proteases, the method comprising injecting into the joint a composition including a therapeutically effective amount of tissue inhibitors of matrix metalloproteinases, thereby lubricating the osteoarthritic joint, wherein the composition includes an amniotic fluid from which the TIMPS originate that is obtained from a pregnant female donor during a Caesarean section procedure wherein the amniotic fluid includes a concentration of IL-6 of at least 329 ng/L, a concentration of IL-8 of at least 421 ng/L, a concentration of IL-1β of at least 3.9 ng/L and a concentration of TNF-α of at least 11.5 ng/L.

A method of treating a joint disease, disorder, or condition in a subject in need thereof, the method comprising injecting a composition including an enriched amniotic fluid comprising a therapeutically effective amount of tissue inhibitors of matrix metalloproteinases (TIMPs) into a joint of the subject, thereby treating the joint disease, disorder, or condition, wherein the amniotic fluid is enriched for endogenous TIMPs whereby the enriched amniotic fluid includes the therapeutically effective amount of the TIMPs, a concentration of α-globulins of at least 12% of a total protein concentration of the enriched amniotic fluid, a concentration of β-globulins of at least 16% of the total protein concentration and a concentration of γ-globulins of at least 12% of the total protein concentration, wherein the joint disease, disorder, or condition is associated with degradation of cartilage by proteases and the amniotic fluid is obtained from a pregnant female donor during a Caesarean section procedure.